AssetMark Inc
ARQT icon

AssetMark Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

AssetMark Inc’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.7K Hold
1,517
– – ﹤0.01% 1859
2025
Q4 		$44.1K Sell
1,517
-343
-18% -$8.78K ﹤0.01% 1761
2025
Q3 		$35.1K Hold
1,860
– – ﹤0.01% 1761
2025
Q2 		$26.1K Hold
1,860
– – ﹤0.01% 1740
2025
Q1 		$29.1K Hold
1,860
– – ﹤0.01% 1599
2024
Q4 		$25.9K Hold
1,860
– – ﹤0.01% 1594
2024
Q3 		$17.3K Hold
1,860
– – ﹤0.01% 1526
2024
Q2 		$17.3K Hold
1,860
– – ﹤0.01% 1409
2024
Q1 		$18.4K Hold
1,860
– – ﹤0.01% 1294
2023
Q4 		$6.01K Hold
1,860
– – ﹤0.01% 1434
2023
Q3 		$9.88K Hold
1,860
– – ﹤0.01% 1335
2023
Q2 		$17.7K Buy
1,860
+255
+16% +$2.83K ﹤0.01% 1227
2023
Q1 		$17.7K Buy
1,605
+250
+18% +$3.62K ﹤0.01% 1205
2022
Q4 		$20.1K Buy
1,355
+440
+48% +$7.69K ﹤0.01% 1203
2022
Q3 		$17K Buy
915
+375
+69% +$8.5K ﹤0.01% 1152
2022
Q2 		$12K Buy
+540
New +$11.1K ﹤0.01% 1197

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return